CYBERMED LIFE - ORGANIC  & NATURAL LIVING

Dietary Modification - Low Carbohydrate-Ketogenic

Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy--the Austrian experience📎

Written by CYBERMED LIFE NEWS
Attachments:
Download this file (Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy--the Austrian experience..pdf)Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy--the Austrian experience..pdf[Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy--the Austrian experience.]167 kB
facebook Share on Facebook
Abstract Title:

Long-term outcome and tolerability of the ketogenic diet in drug-resistant childhood epilepsy--the Austrian experience.

Abstract Source:

Seizure. 2010 Sep;19(7):404-8. Epub 2010 Jul 2. PMID: 20598586

Abstract Author(s):

Anastasia Dressler, Benjamin Stöcklin, Eva Reithofer, Franz Benninger, Michael Freilinger, Erwin Hauser, Edith Reiter-Fink, Rainer Seidl, Petra Trimmel-Schwahofer, Martha Feucht

Article Affiliation:

Department of Paediatrics, Medical University Vienna, Waehringer Guertel 18-20, A-1090 Wien, Vienna, Austria.

Abstract:

PURPOSE: To evaluate the long-term efficacy/tolerability of the ketogenic diet (KD) in paediatric drug-resistant epilepsies.

METHODS: Data from children who were treated between 1999 and 2008 and had continuous follow-up of at least 6 months after initiation of the KD were analysed retrospectively. Response was defined as>or = 50% seizure reduction. Treatment effects on EEG, developmental outcome and the "outcome-predictive" value of various clinical factors were also assessed.

RESULTS: 50 children (22 boys; mean age 4.5 years+/-3.55) were included. Mean follow-up was 3.93+/-2.95. 50% of the patients were responders, 48% of them became seizure free. 50% were non-responders, 20% of them deteriorated. In responders, EEG background activity improved significantly (p=0.014) and a significantly lower rate of epileptic discharges (p=0.009) was seen after 6 months. In addition, neurological examination findings demonstrated significant developmental progress (p=0.038). Favourable treatment outcome was associated with a shorter disease duration (p=0.025) and generalised tonic clonic seizures (p=0.059). No further significant outcome predictors were detected. However, response was 44% in patients with infantile spasms, 62.5% in those with Dravet syndrome and 50% in Lennox-Gastaut-syndrome. Side effects occurred in 28%, but discontinuation of the KD was not required in any case. They most often observed with concomitant topiramate (p=0.001) and valproate (p=0.046).

CONCLUSION: Despite the retrospective nature of the study and the inhomogeneous patient sample, we found good long-term effects of the KD on seizure frequency, EEG and neurological development.


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.